ReviewVisceral medicine2017
Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.
Review in Visceral medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Successful endoscopic resection of large duodenal bulb carcinoid tumor: a case report.Annals of medicine and surgery (2012) · 2026Article
- Concomitant gastric cancer and neuroendocrine tumours in the stomach: a rare case series of 3 patients and a literature review.Diagnostic pathology · 2025Review
- Endoscopic full-thickness resection: A definitive solution for local complete resection of small rectal neuroendocrine neoplasms.World journal of gastroenterology · 2025Article
- Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.Diagnostics (Basel, Switzerland) · 2024Article
- Treatment outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumors.Journal of gastrointestinal oncology · 2024Article
- Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.Digestive diseases and sciences · 2024Review
- Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?Medicina (Kaunas, Lithuania) · 2023Review
- Efficacy of Endoscopic Resection for Rectal Neuroendocrine Tumors Smaller than 15 mm.Digestive diseases and sciences · 2023Article
- Endoscopic techniques for gastric neuroendocrine tumors: An update.World journal of gastrointestinal endoscopy · 2023Review
- Endoscopic treatment and management of rectal neuroendocrine tumors less than 10 mm in diameter.World journal of gastrointestinal endoscopy · 2023Review
- Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.World journal of gastroenterology · 2022Article
- Neuroendocrine tumour of the descending part of the duodenum complicated with schwannoma: A case report.World journal of clinical cases · 2022Article
- Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.World journal of gastroenterology · 2022Review
- The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5.Experimental and therapeutic medicine · 2021Article
- Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists.GE Portuguese journal of gastroenterology · 2021Review
- Comparison of endoscopic resection techniques for duodenal neuroendocrine tumors: systematic review.Endoscopy international open · 2021Review
- Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors.BMC gastroenterology · 2021Article
- Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors.Cancers · 2021Review
- Impact of enteroscopy on diagnosis and management of small bowel tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasias (NEN) of the stomach, duodenum, pancreas, appendix, or rectum that are ≤1 cm in size as well as well-differentiated with World Health Organization grade 1 (G1) can be considered 'early' neuroendocrine tumors; they have a very good prognosis. Regarding prognosis, neuroendocrine tumors (NET) G1 must be distinguished from well-differentiated NET G2 and poorly differentiated neuroendocrine carcinomas (NEC) G3. NET are increasing, with a rise in the age-adjusted incidence in the USA by about 700% in the last 40 years. Earlier diagnosis of NET is one of the main epidemiological changes of clinically detected NEN. The general availability of high-resolution endoscopy and advanced radiological imaging techniques has contributed to a shift in the discovery to smaller-sized (≤10 mm) gastrointestinal and pancreatic NET and earlier tumor stages at diagnosis. Thus, screening colonoscopy is effective in the early diagnosis not only of colorectal adenomas and adenocarcinomas but also of rectal NET. Endoscopic resection is the treatment of choice in NET G1 of the stomach, duodenum (despite gastrinoma), and rectum that are ≤10 mm in size, do not infiltrate the muscularis propria (T1), and do not show angioinvasion (V0, L0). Similarly, histologically proven, early pancreatic NET G1 (≤10 mm) may be managed conservatively by regular surveillance. In contrast, small (≤1 cm) NET G1 of the jejunum or ileum are not 'early' tumors and have to be resected surgically with lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.